Texas recently released its first round of numbers from the “unwinding” of the Medicaid continuous coverage requirement. The state’s approach may be contributing to the coverage losses.
Arkansas has a history of disenrolling people from Medicaid even though they’re still eligible. It’s happening again.
Millions of Americans are projected to lose Medicaid coverage soon. If you haven’t heard, that’s because the program is functioning as intended.
A recent piece we wrote for MedPage Today lays out how the end of the public health emergency is going to have a catastrophic effect on Medicaid coverage, even among people who are still eligible.
As part of an executive order signed by President Biden, the Centers for Medicare and Medicaid aim to reduce the administrative burden of applying for CHIP and Medicaid.
Access to care is limited for Medicaid enrollees in part because Medicare and private insurers provide physicians with higher payment rates.
Most research considers the impact Medicaid expansion has on newly eligible enrollees. Far less is known about the ripple effect expansion has on individuals who were already enrolled.
In a new study published in JAMA Internal Medicine, researchers sought to bridge this gap by looking at how commercially-run Medicaid plans compared to Medicaid-focused plans relative to enrollee utilization of outpatient and acute care services.
I’ve got a new article out at The Atlantic digging into that surprisingly thorny question. At stake here is whether the Biden team can move quickly
Paul Shafer is an assistant professor of health law, policy, and management at the Boston University School of Public Health, follow him on Twitter @shaferpr.
Paul Shafer is an assistant professor of health law, policy, and management at the Boston University School of Public Health. Nicole Huberfeld is a professor
Today, rising brand-name prescription drug prices (and increasingly-prevalent high-deductible health plans) pose a threat to Americans’ financial security and to the health of our communities. Past political controversies notwithstanding, using cost-effectiveness research and analyses to pay for high-value prescription drugs can help US patients afford the drugs they need as prices continue to rise.
Work posted here under copyright © of the authors • Details on the Site Policies page
